Disintegrin variants and pharmaceutical uses thereof

Woei-Jer Chuang (Inventor)

Research output: Patent

Abstract

Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin .alpha.v.beta.3 receptor-antagonist activity and substantially reduced integrin .alpha.llb.beta.3 and/or .alpha.5.beta.1 receptor-blocking activity as compared to a wild-type disintegrin.
Original languageEnglish
Patent number153383
Publication statusPublished - 2009 Jul 29

Fingerprint

Disintegrins
Integrins
Pharmaceutical Preparations
Peptides

Cite this

@misc{526033e1fe7546398b9ee5c168020313,
title = "Disintegrin variants and pharmaceutical uses thereof",
abstract = "Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin .alpha.v.beta.3 receptor-antagonist activity and substantially reduced integrin .alpha.llb.beta.3 and/or .alpha.5.beta.1 receptor-blocking activity as compared to a wild-type disintegrin.",
author = "Woei-Jer Chuang",
year = "2009",
month = "7",
day = "29",
language = "English",
type = "Patent",
note = "153383",

}

TY - PAT

T1 - Disintegrin variants and pharmaceutical uses thereof

AU - Chuang, Woei-Jer

PY - 2009/7/29

Y1 - 2009/7/29

N2 - Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin .alpha.v.beta.3 receptor-antagonist activity and substantially reduced integrin .alpha.llb.beta.3 and/or .alpha.5.beta.1 receptor-blocking activity as compared to a wild-type disintegrin.

AB - Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin .alpha.v.beta.3 receptor-antagonist activity and substantially reduced integrin .alpha.llb.beta.3 and/or .alpha.5.beta.1 receptor-blocking activity as compared to a wild-type disintegrin.

M3 - Patent

M1 - 153383

ER -